Skip to main content
logo
NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
12.06
+0.05 (0.42%)
Mar 13, 2026, 4:00 PM EDT - Market closed

Company Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.

Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.

NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

NovoCure Limited
NovoCure logo
CountrySwitzerland
Founded2000
IPO DateOct 2, 2015
IndustryMedical Devices
SectorHealthcare
Employees1,605
CEOFrank Leonard

Contact Details

Address:
Neuhofstrasse 21
Baar, 6340
Switzerland
Websitenovocure.com

Stock Details

Ticker SymbolNVCR
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001645113
CUSIP NumberG6674U108
ISIN NumberJE00BYSS4X48
SIC Code3841

Key Executives

NamePosition
Frank LeonardChief Executive Officer
William F. DoyleExecutive Chairman
Barak Ben-AryeGeneral Counsel
Dr. Uri Weinberg M.D., Ph.D.Chief Innovation Officer and Chief Medical Officer
Christoph BrackmannChief Financial Officer
Mukund ParavasthuChief Operating Officer
Michael PuriChief Human Resources Officer

Latest SEC Filings

DateTypeTitle
Mar 5, 2026144Filing
Mar 4, 2026144Filing
Mar 4, 2026144Filing
Mar 4, 2026144Filing
Mar 4, 2026144Filing
Mar 3, 2026144Filing
Mar 2, 2026144Filing
Mar 2, 2026144Filing
Feb 27, 2026144Filing
Feb 27, 2026144Filing
View All SEC Filings